Top

Published in:

01-06-2012 | Letter to the Editor

The SNP rs895819 in miR-27a is not associated with familial breast cancer risk in Italians

Authors: Irene Catucci, Paolo Verderio, Sara Pizzamiglio, Loris Bernard, Valentina Dall’olio, Domenico Sardella, Fernando Ravagnani, Laura Galastri, Monica Barile, Bernard Peissel, Daniela Zaffaroni, Siranoush Manoukian, Paolo Radice, Paolo Peterlongo

Published in: Breast Cancer Research and Treatment | Issue 2/2012

Excerpt

To the Editor, …

Lovat F, Valeri N, Croce CM (2011) MicroRNAs in the pathogenesis of cancer. Semin Oncol 38:724–733PubMedCrossRef

Le Quesne J, Caldas C (2010) Micro-RNAs and breast cancer. Mol Oncol 4:230–241PubMedCrossRef

Ryan BM, Robles AI, Harris CC (2010) Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer 10:389–402PubMedCrossRef

Catucci I, Yang R, Verderio P, Pizzamiglio S, Heesen L, Hemminki K, Sutter C, Wappenschmidt B, Dick M, Arnold N, Bugert P, Niederacher D, Meindl A, Schmutzler RK, Bartram CC, Ficarazzi F, Tizzoni L, Zaffaroni D, Manoukian S, Barile M, Pierotti MA, Radice P, Burwinkel B, Peterlongo P (2010) Evaluation of SNPs in miR-146a, miR196a2 and miR-499 as low-penetrance alleles in German and Italian familial breast cancer cases. Hum Mutat 31:E1052–E1057PubMedCrossRef

Tian T, Xu Y, Dai J, Wu J, Shen H, Hu Z (2010) Functional polymorphisms in two pre-microRNAs and cancer risk: a meta-analysis. Int J Mol Epidemiol Genet 1:358–366PubMed

Gao LB, Bai P, Pan XM, Jia J, Li LJ, Liang WB, Tang M, Zhang LS, Wei YG, Zhang L (2011) The association between two polymorphisms in pre-miRNAs and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 125:571–574PubMedCrossRef

Li W, Duan R, Kooy F, Sherman SL, Zhou W, Jin P (2009) Germline mutation of microRNA-125a is associated with breast cancer. J Med Genet 46:358–360PubMedCrossRef

Peterlongo P, Caleca L, Cattaneo E, Ravagnani F, Bianchi T, Galastri L, Bernard L, Ficarazzi F, Dall’olio V, Marme F, Langheinz A, Sohn C, Burwinkel B, Giles GG, Baglietto L, Severi G, Odefrey FA, Southey MC, Osorio A, Fernández F, Alonso MR, Benítez J, Barile M, Peissel B, Manoukian S, Radice P (2011) The rs12975333 variant in the miR-125a and breast cancer risk in Germany, Italy, Australia and Spain. J Med Genet 48:703–704PubMedCrossRef

Yang R, Schlehe B, Hemminki K, Sutter C, Bugert P, Wappenschmidt B, Volkmann J, Varon R, Weber BH, Niederacher D, Arnold N, Meindl A, Bartram CR, Schmutzler RK, Burwinkel B (2009) A genetic variant in the pre-miR-27a oncogene is associated with a reduced familial breast cancer risk. Breast Cancer Res Treat 121:693–702PubMedCrossRef

10.

Manoukian S, Peissel B, Pensotti V, Barile M, Cortesi L, Stacchiotti S, Terenziani M, Barbera F, Pasquini G, Frigerio S et al (2007) Germline mutations of TP53 and BRCA2 genes in breast cancer/sarcoma families. Eur J Cancer 43:601–606PubMedCrossRef

11.

Hosmer DW, Lemeshow S (1989) Applied logistic regression. John Wiley & Sons, New York

12.

Zhang M, Jin M, Yu Y, Zhang S, Wu Y, Liu H, Liu H, Chen B, Li Q, Ma X, Chen K (2011) Associations of miRNA polymorphisms and female physiological characteristics with breast cancer risk in Chinese population. Eur J Cancer Care. doi:10.1111/j.1365-2354.2011.01308.x

13.

Sun Q, Gu H, Zeng Y, Xia Y, Wang Y, Jing Y, Yang L, Wang B (2010) Hsa-mir-27a genetic variant contributes to gastric cancer susceptibility through affecting miR-27a and target gene expression. Cancer Sci 101:2241–2247PubMedCrossRef

Title: The SNP rs895819 in miR-27a is not associated with familial breast cancer risk in Italians
Authors: Irene Catucci
Paolo Verderio
Sara Pizzamiglio
Loris Bernard
Valentina Dall’olio
Domenico Sardella
Fernando Ravagnani
Laura Galastri
Monica Barile
Bernard Peissel
Daniela Zaffaroni
Siranoush Manoukian
Paolo Radice
Paolo Peterlongo
Publication date: 01-06-2012
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2012
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-012-2011-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2012

Upper limb progressive resistance training and stretching exercises following surgery for early breast cancer: a randomized controlled trial

Thinking beyond the tumor to better understand chronic symptoms in breast cancer survivors

Long-term follow-up of Jewish women with a BRCA1 and BRCA2 mutation who underwent population genetic screening

The in vitro and in vivo effects of human umbilical cord mesenchymal stem cells on the growth of breast cancer cells

Quality of life among Egyptian women with breast cancer after sparing mastectomy and immediate autologous breast reconstruction: a comparative study

Cyclooxygenase-2 expression in proliferative Ki-67-positive breast cancers is associated with poor outcomes

Keynote webinar | Spotlight on antibody–drug conjugates in cancer